Nuvalent Inc

NASDAQ:NUVLUnited States

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Contact Information

Headquarters

One Broadway, 14th FloorCAMBRIDGE, MA, United States 02142

Phone

857-357-7000

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

Anna Protopapas

President, Chief Executive Officer, Director

James Porter

Chief Financial Officer, Treasurer

Alexandra Balcom

Chief Development Officer

Darlene Noci

Chief Medical Officer

Christopher Turner